ponatinib
otsuka,takeda,incyte
['cml', 'ponatinib']
#noeticinsight reporting live from #ash22 if 2 tki therapies fail in chronic-phase cml pts w/o t315i mutations, ponatinib is a credible 3l option, according to the analysis of data combined from the optic and pace studies and the university of texas m.d. anderson cancer center 